Bicycle Therapeutics Showcases Innovative Oncology Solutions at J.P. Morgan Healthcare Conference

Bicycle Therapeutics Advances Innovative Therapeutics at J.P. Morgan Healthcare Conference

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company headquartered in Cambridge, England, is poised to showcase its groundbreaking work in drug development at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 14 at 5:15 p.m. PT, the presentation will outline the company’s innovative approach using its proprietary Bicycle® technology. This technology centers on fully synthetic bicyclic peptides, which offer unique structural advantages that enhance binding affinity and selectivity for therapeutic targets, especially in oncology.

The company's portfolio includes several promising clinical candidates. Notably, zelenectide pevedotin (formerly BT8009) is a Bicycle® Toxin Conjugate designed to target the tumor antigen Nectin-4, which is crucial for addressing various cancers. Additionally, BT5528 aims to tackle the historically challenging EphA2 target, while BT7480, another Bicycle Tumor-Targeted Immune Cell Agonist®, also focuses on Nectin-4 but is specifically engineered to activate the immune response via CD137. This diverse array of candidates underscores Bicycle Therapeutics' commitment to addressing unmet medical needs in oncology.

Beyond its current applications, Bicycle Therapeutics is exploring the potential of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical uses. The company is also actively seeking partnerships to broaden the application of its innovative technology beyond oncology, indicating a strategic vision aimed at expanding its therapeutic reach. With operations in both the UK and Cambridge, Massachusetts, Bicycle Therapeutics stands at the forefront of the pharmaceutical industry, dedicated to developing treatments for diseases that remain inadequately addressed by existing therapies.

Bicycle Therapeutics' participation in the J.P. Morgan Healthcare Conference represents a strategic opportunity to engage with investors and industry peers about its advancements in drug development. The live webcast ensures that a broader audience can access insights into the company’s innovative pipeline and vision for the future. For more information, stakeholders can visit their website at www.bicycletherapeutics.com.

As the landscape of oncology treatment continues to evolve, Bicycle Therapeutics' commitment to leveraging its proprietary technology for innovative therapeutic solutions positions the company as a key player in the pharmaceutical industry.